Sequential afatinib and osimertinib in NSCLC patients

This Publication Perspective summarizes an article originally published in Advances in Therapy entitled ‘Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib’. The non-interventional, global, multicenter GioTag study assessed sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small cell lung cancer. The post-hoc analysis included patients who received the approved 40-mg starting dose of afatinib. The findings support the clinical benefit for sequential afatinib and osimertinib.

Original publication:

Observational study of sequential afatinib and osimertinib in EGFR mutation-positive NSCLC: patients treated with a 40-mg starting dose of afatinib
Nobuyuki Yamamoto, Takeshi Mera, Angela Märten & Maximilian J Hochmair
Advances in Therapy 37, 759–769 (2020) DOI: 10.1007/S12325-019-01187-y